Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher

Impact · against what's priced in

The European regulatory recommendation for Foundayo is a positive but largely priced-in event for Eli Lilly, as the market already accounts for the oral pill's initial launch and market penetration. While Novo Nordisk faces competitive pressure from Foundayo's superior dosing and label, the news is not a primary driver for Amgen.

LLY+0.10

Already priced in

The price assumes

Current GLP-1 market dominance and the initial U.S. launch of the oral pill Foundayo